Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort
复制标题
DOI：
10.1093/infdis/jiaa617
复制
发表时间：
2021-06-01
影响因子：
6.4
通讯作者：
Faust, Helena
中科院分区：
文献类型：
--
作者：
Kann, Hanna;Lehtinen, Matti;Faust, Helena
背景。人乳头瘤病毒 (HPV) 会导致多种人类癌症。二价 (Cervarix) 和四价 (qGardasil) HPV 疫苗均含有主要致癌 HPV 16 型和 18 型的病毒样颗粒，而且还针对某些非疫苗类型具有交叉保护作用。然而，有关 HPV 疫苗交叉反应抗体反应长期可持续性的数据很少。方法。从基于人群的芬兰孕妇队列生物库中检索 16-17 岁二价 (n = 730) 或四价 (n = 337) HPV 疫苗免疫后 7-12 年后捐赠的血清样本。使用多重假病毒粒子结合测定法测定针对 HPV 6、11、16、18、31、33、35、39、45、51、52、56、58、59、68 和 73 型的血清抗体水平。使用硫氰酸铵处理评估抗体亲合力。结果。 HPV31、33、35、45、51、52、58、59、68 和 73 的血清阳性越来越常见（P
Background. Human papillomaviruses (HPV) cause several human cancers. Bivalent (Cervarix) and quadrivalent (qGardasil) HPV vaccines both contain virus-like particles of the major oncogenic HPV types 16 and 18, but also cross-protect against some nonvaccine types. However, data on long-term sustainability of the cross-reactive antibody responses to HPV vaccines are scarce.Methods. Serum samples donated 7-12 years after immunization at age 16-17 years with bivalent (n = 730) or quadrivalent (n = 337) HPV vaccine were retrieved from the population-based Finnish Maternity Cohort biobank. Serum antibody levels against HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73 were determined using multiplex pseudovirion binding assay. Antibody avidity was assessed using ammonium thiocyanate treatment.Results. Seropositivity for HPV31, 33, 35, 45, 51, 52, 58, 59, 68, and 73 was increasingly common (P